COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Retina & Vitreous

Brolucizumab 6 mg Drug Product Intended for Commercialization

  • A 24-Week, Double-Masked, Multicenter, Two-Arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients with Neovascular Age-Related Macular Degeneration who have Completed the Crth258a2301 Study
  • PI: William R. Freeman, MD

Efficacy of Zimura™ in Subjects with Geographic Atrophy (GA)

  • A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Zimura™ (Anti-Complement Factor 5 Aptamer) in Subjects with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration
  • PI: William R. Freeman, MD

Intravitreal Opt-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone

  • A Dose-Ranging Study of Intravitreal Opt-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration (Wet AMD)
  • PI: Daniel L. Chao, MD, PhD

KESTREL

  • A Two-Year, Three-Arm, Randomized, Double-Masked,  Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)
  • Nudleman Eric, M.D., Ph.D.

Lampalizumab Administered Intravitreally

  • A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • PI: Henry Ferreyra MD

Lampalizumab in Patients with Geographic Atrophy Secondary

  • A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study
  • PI: Henry Ferreyra, MD

OAKS

  • A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy 2nd to Age-Related Macular Degeneration (OAKS)
  • Chao Daniel L., M.D., Ph.D.

PANDA

  • A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (PANDA)
  • Chao Daniel L., M.D., Ph.D.

PORTAL

  • A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-related Macular Degeneration (PORTAL)
  • Freeman William R., M.D.

RHINE

  • A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (RHINE)
  • Chao Daniel L., M.D., Ph.D.

Rth258 Versus Aflibercept

  • A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of Rth258 Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
  • PI: William R. Freeman, Md
  • Sub-I: Eric Nudleman, MD, PhD, Daniel L. Chao, MD, PhD

SAPPHIRE

  • Suprachoroidal Injection of Triamcinolone Acetonide with IVT Aflibercept in Subjects with Macular Edema Following Rvo (SAPPHIRE) 
  • Chao Daniel L., M.D., Ph.D.

Suprachoroidal Cls-Ta

  • A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal Cls-Ta in Conjunction with Intravitreal Aflibercept in Subjects with Central Retinal Vein Occlusion
  • PI: Daniel L. Chao, MD, PhD 
  • Sub-I: Eric Nudleman, MD, PhD, William R. Freeman, MD

TENAYA

  • A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of FARICIMAB in Patients with Age-Related Macular Degeneration (TENAYA)
  • Chao Daniel L., M.D., Ph.D.


Show additional content areas below